Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

March 31, 2011

Conditions
Gastric Cancer
Interventions
DRUG

Cediranib

Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.

DRUG

Cisplatin

Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.

DRUG

S-1

Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.

DRUG

Cisplatin

60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.

DRUG

Capecitabine

Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.

Trial Locations (4)

Unknown

Research Site, Nagoya

Research Site, Sayama

Research Site, Sunto-gun

Research Site, Chūō

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00960349 - Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients | Biotech Hunter | Biotech Hunter